| Name | (2S,4R,5aS,9cS)-5a-Hydroxy-2-methyl-4-(4-oxo-3(4H)-quinazolinyl)-4,5,5a,9c-tetrahydro-3H-2a,9b-diazacyclopenta[jk]fluorene-1,3(2H)-dione |
|---|---|
| Synonyms |
Chaetominine
(2S,4R,5aS,9cS)-5a-Hydroxy-2-methyl-4-(4-oxo-3(4H)-quinazolinyl)-4,5,5a,9c-tetrahydro-3H-2a,9b-diazacyclopenta[jk]fluorene-1,3(2H)-dione cc-559 3H-2a,9b-Diazacyclopenta[jk]fluorene-1,3(2H)-dione, 4,5,5a,9c-tetrahydro-5a-hydroxy-2-methyl-4-(4-oxo-3(4H)-quinazolinyl)-, (2S,4R,5aS,9cS)- chaetomimine (2S,4R,5aS,9cS)-5a-hydroxy-2-methyl-4-(4-oxoquinazolin-3(4H)-yl)-4,5,5a,9c-tetrahydro-3H-2a,9b-diazacyclopenta[jk]fluorene-1,3(2H)-dione |
| Description | Chaetominine is an alkaloidal metabolite. Chaetominine has cytotoxicity against human leukemia K562 and colon cancer SW1116 cell lines. Chaetominine reduces MRP1-mediated drug resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells[1][2]. |
|---|---|
| Related Catalog | |
| Target |
PI3K, Akt, Nrf2[2] |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 720.7±70.0 °C at 760 mmHg |
| Molecular Formula | C22H18N4O4 |
| Molecular Weight | 402.40 |
| Flash Point | 389.6±35.7 °C |
| Exact Mass | 402.132813 |
| PSA | 95.74000 |
| LogP | 0.61 |
| Vapour Pressure | 0.0±2.4 mmHg at 25°C |
| Index of Refraction | 1.822 |